Join to access to all OVN content. Join for Free
How to create HIGH performing MSLs, teams and MSL leaders
field medical development evolving role of MSLs executive coaching soft skills for MSLs high-performing MSL teams

How to create HIGH performing MSLs, teams and MSL leaders


Share This Article


Summary

In this episode, Mike Penkethman delves into field medical development and the evolving role of MSLs. He emphasizes the importance of executive coaching, soft skills, and adapting to pandemic-driven changes. Mike provides insights into the attributes of high-performing MSLs, especially in virtual settings, and discusses the evaluation of MSL teams. He highlights strategies for team development, goal setting, and the significance of networking and centers of influence. The conversation also covers practical advice on verbalizing and documenting goals, honing soft skills, and crafting a compelling CV for aspiring MSLs. The episode concludes with reflective closing remarks and gratitude.

Check out my latest podcast with Mike Penkethman, Career Coach and President of the Pilotage Group. We discuss how to create high-performing MSLs, teams, and MSL leaders.

We discuss:

 What are the key attributes of high performing MSL
 What MSL interactions will look like in the future
 What do MSL Leaders look for in MSLs
 What is the most successful approach to KOL interactions
 What value and resources can (and should) MSLs bring to their KOLs

Click for Source
field medical development, evolving role of MSLs, executive coaching, soft skills for MSLs, high-performing MSL teams

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Article
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
OVN Avatar J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Article
Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer
OVN Avatar Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Explore OVN